• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Mass. General Hospital Utilizes InterSystems for Genomics Research

by HITC Staff 01/21/2015 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

InterSystems Brings Big Data Expertise to Global Alliance for Genomics and Health

The Center for Integrated Diagnostics (CID) at Massachusetts General Hospital (MGH) is collaborating with InterSystems, a provider of software for connected healthcare, to help accelerate innovations in molecularly targeted medicine.

Collaboration Overview

MGH CID is exploring how the InterSystems HealthShare® health informatics platform can support genomic research and clinical innovations. HealthShare enables interoperability across multiple systems and data formats, making it possible to capture, share, understand, and act on large volumes of structured and unstructured health information. The platform is used by private hospitals and health systems, regional and statewide health information exchanges, and entire nations.

The CID research is specifically leveraging HealthShare to target large data set management and cross-organizational collaboration, to allow integration of genetic and clinical data to improve clinical decision support and to enhance genomic knowledge discovery.

The CID’s mission is to foster the development of actionable clinical diagnostics and to accelerate the adoption of novel personalized therapies. The CID genetically fingerprints patient tumors across the complete spectrum of disease sites to guide targeted therapies, thereby enhancing the efficacy of drug treatments and supporting new clinical trial designs. Patients whose cancers harbor susceptible genotypes can be offered the most appropriate clinical treatment.

“While we have already made strides in the cancer field, it is our goal to expand our testing to other disciplines,” said A. John Iafrate, M.D.-Ph.D, founder and director of the CID. As a molecular pathologist, Dr. Iafrate oversees research focused on lung and brain tumors, and he has been closely involved in the clinical development of the anti-cancer drug Crizotinib and companion diagnostics in ALK- and ROS1-positive lung cancers.

The Centers for Medicare & Medicaid Services (CMS) regulates all laboratory testing performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA). Using these guidelines, the CID’s patient analyses are performed as CLIA-certified clinical tests, and results are generated within a timeframe that allows for direct patient care decision making.

The CID laboratory pursues retrospective and corollary research studies to support the expansion of its genotyping profiles. To accomplish these goals, the lab utilizes a number of molecular and cellular techniques, including fluorescent in situ hybridization (FISH), qPCR, DNA sequencing, SNP-based approaches and DNA sizing analyses. The combination of these approaches allows for the detection of somatic genetic aberrations on multiple levels, including gene copy number, point mutations and small deletions and insertions.

Both InterSystems and MGH are partner members of the Global Alliance for Genomics and Health, which was formed in 2013 to help accelerate the potential of genomic medicine to advance human health. The alliance brings together over 220 leading institutions working in healthcare, research, disease advocacy, life science, and information technology. The partners in the Global Alliance are working together to create a common framework of harmonized approaches to enable the responsible, voluntary, and secure sharing of genomic and clinical data.

“Dr. Iafrate is widely respected for his pioneering work in genomics research, and Mass. General Hospital has been a wellspring of health technology innovation, including the first programming language for doctors, which helped spawn a raft of health IT companies – including InterSystems. We are very proud that our technology platform is supporting this important work,” said Paul Grabscheid, Vice President of Strategic Planning, InterSystems.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: InterSystems

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |